Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOFRONTERA INC.

(BFRI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Biofrontera Obtains Notice of Allowance for US Patent Related to Nanoemulsion Technology

09/06/2022 | 11:55am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIOFRONTERA AG 0.00% 1.58 Delayed Quote.11.74%
BIOFRONTERA INC. -2.05% 0.9548 Delayed Quote.-87.04%
All news about BIOFRONTERA INC.
11/30Biofrontera Inc. to Participate in Benchmark's 11th Annual Discovery One-on-One Investo..
GL
11/28Biofrontera inc. to participate in renmark's virtual non-deal roadshow series on wednes..
GL
11/28Biofrontera inc. to participate in renmark's virtual non-deal roadshow series on wednes..
AQ
11/21Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz«-PDT for the Treatment o..
GL
11/21Biofrontera Inc. to Launch Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Trea..
CI
11/14Transcript : Biofrontera Inc., Nine Months 2022 Earnings Call, Nov 14, 2022
CI
11/14BIOFRONTERA INC. Management's Discussion and Analysis of Financial Condition and Resul..
AQ
11/14Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended S..
CI
11/14Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
11/14Biofrontera Inc. Reports Third Quarter 2022 Financial Results and Provides a Business U..
GL
More news
Analyst Recommendations on BIOFRONTERA INC.
More recommendations
Financials (USD)
Sales 2022 31,4 M - -
Net income 2022 0,86 M - -
Net Debt 2022 - - -
P/E ratio 2022 21,2x
Yield 2022 -
Capitalization 25,5 M 25,5 M -
Capi. / Sales 2022 0,81x
Capi. / Sales 2023 0,56x
Nbr of Employees 69
Free-Float 57,6%
Chart BIOFRONTERA INC.
Duration : Period :
Biofrontera Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,95 $
Average target price 15,50 $
Spread / Average Target 1 523%
EPS Revisions
Managers and Directors
Erica L. Monaco Chief Executive, Operating & Financial Officer
Fred Leffler Chief Financial Officer
Hermann LŘbbert Executive Chairman
Armin Ollig Vice President-Information Technology
Daniel Hakansson General Counsel & Head-Compliance
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA INC.-87.04%26
JOHNSON & JOHNSON2.73%463 286
ELI LILLY AND COMPANY34.60%353 267
ABBVIE INC.20.43%293 450
PFIZER, INC.-12.31%290 657
NOVO NORDISK A/S22.08%287 434